Rethinking Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis in Patients with Cirrhosis
➡️Standard of care since the 1990s and is currently recommended by several major GI societies
➡️Weak supporting evidence
➡️No clear mortality benefit
https://doi.org/10.1093/cid/ciaf047
#IDSky
➡️Standard of care since the 1990s and is currently recommended by several major GI societies
➡️Weak supporting evidence
➡️No clear mortality benefit
https://doi.org/10.1093/cid/ciaf047
#IDSky
1 / 2
Comments
Thank you! Was just talking about this with a member of my team this afternoon!
https://pubmed.ncbi.nlm.nih.gov/28994123/
https://pubmed.ncbi.nlm.nih.gov/27512927/
@ebtapper.bsky.social
@jasmohanbajaj.bsky.social
Might be answered in part by an ongoing/fully enrolled trial that is for HE prevention but enrolled mainly people with ascites
Found this digest, to your point. Seems like studies too small/flawed huh.
From Hepatology ‘21 “The Use of Rifaximin in Patients With Cirrhosis” also with @jasmohanbajaj.bsky.social
https://journals.lww.com/hep/fulltext/2021/09000/the_use_of_rifaximin_in_patients_with_cirrhosis.41.aspx